Researchers combined Raman microscopy with gene expression data at single-cell resolution from the same cells, and AI, to develop RamanOmics, a noninvasive way to detect biomarkers...
Immunotherapy has transformed the treatment of many cancers, and few targets have proven as consequential as the interaction between the programmed cell death protein 1 receptor,...
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast...
Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific...
As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.
Mayo Clinic recently launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as...
As we age, some of the cells in our body enter a state of senescence, in which they stop dividing but do not die. Those senescent...
Validated on the CellXpress.ai automated cell culture system, the new workflow combines organoid biology expertise and laboratory automation to help researchers reduce variability, expand scale, and...
The latest company to spin out of a Stanford Medicine lab is a biotech undertaking with 37,000 employees—and none of them are human. There's no lab...
Scan to Read